KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Q3 2025 value amounting to 0.03%.

  • Supernus Pharmaceuticals' Return on Capital Employed fell 900.0% to 0.03% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.03%, marking a year-over-year decrease of 900.0%. This contributed to the annual value of 0.08% for FY2024, which is 800.0% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Return on Capital Employed stood at 0.03% for Q3 2025, which was down 900.0% from 0.06% recorded in Q2 2025.
  • Supernus Pharmaceuticals' Return on Capital Employed's 5-year high stood at 0.12% during Q1 2021, with a 5-year trough of 0.03% in Q3 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' median Return on Capital Employed value was 0.05% (recorded in 2022), while the average stood at 0.05%.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Return on Capital Employed skyrocketed by 800bps in 2024 and then crashed by -900bps in 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Return on Capital Employed (Quarter) stood at 0.07% in 2021, then tumbled by -31bps to 0.05% in 2022, then crashed by -112bps to 0.01% in 2023, then skyrocketed by 1545bps to 0.08% in 2024, then plummeted by -145bps to 0.03% in 2025.
  • Its Return on Capital Employed was 0.03% in Q3 2025, compared to 0.06% in Q2 2025 and 0.07% in Q1 2025.